VYGR: Tau-targeting therapies and novel delivery platforms advance toward key clinical and partnership milestones
Three major catalysts this year include tau-targeting therapies, capsid proof-of-concept, and NeuroShuttle platform progress. Key tau antibody and gene therapy programs are advancing toward clinical milestones, with partnering planned after proof-of-concept data. Multiple collaborations and new del…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.